Clinical Trials Search
A Multicenter, Non-Randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma (HCC) with No Prior Systemic Therapy.
The purpose of this study is to assess if regorafenib in combination with pembrolizumab is safe and tolerated in patients with liver cancer. The study will determine the highest dose of regorafenib that can be safely given in combination with pembrolizumab. The study also aims to evaluate whether this new combination is able to slow the tumor growth or even shrink the tumor.